Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics. The company's core business revolves around selectively degrading disease-causing proteins by harnessing the body's natural protein degradation system, utilizing its proprietary Targeted Protein Degradation (TPD) platform, Pegasus™. Its mission is to reinvent the treatment of human disease and build a global medicines company that revolutionizes healthcare through novel modalities. Kymera Therapeutics is headquartered in Watertown, Massachusetts.

The company's pipeline focuses on deploying TPD against disease targets in areas of significant patient need, primarily in immunology and oncology. Key product candidates include KT-621, an oral STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and eosinophilic asthma, and KT-579, an IRF5 degrader targeting autoimmune diseases like lupus and rheumatoid arthritis. Kymera also has partnered programs, such as KT-485, an IRAK4 degrader in collaboration with Sanofi for immuno-inflammatory diseases, and KT-200, a CDK2 molecular glue degrader with Gilead Sciences for oncology applications, including breast cancer.

In recent news, Kymera Therapeutics reported strong first-quarter 2026 revenue, surpassing analyst expectations, largely driven by its collaboration with Gilead Sciences. Gilead Sciences exercised its option to license KT-200, triggering a $45 million milestone payment in Q2 2026. The U.S. FDA granted Fast Track designation for KT-621 in moderate to severe eosinophilic asthma in April 2026. Led by Founder, President, and CEO Nello Mainolfi, Ph.D., the company maintains a cash runway projected into 2029, supporting its expanding clinical pipeline.